This antibody may be diluted to a titer of 1:25-1:100 in an ABC method. We suggest an incubation period of 30-60 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation and dilutions should be determined by the user.
Tonsil or Spleen tissue sections
This antibody reacts with human myeloperoxidase. It stains granules of neutrophils granulocytes in spleen, bone marrow, tonsil and blood smears.
PBS pH7.5 containing 1%BSA and 0.05% sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.
0.5mg/ml(Please refer to the vial label for the specific concentration.)
Myeloperoxidase isolated from human granulocytes
Protein A purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Myeloperoxidase is a hemoprotein that is abundantly expressed in neutrophils and secreted during their activation. Native Myeloperoxidase is represented as a covalently bound tetrameric complex of two glycosylated alpha chains (MW 59 - 64 kDa) and two unglycosylated beta chains (MW 14 kDa) with total MW 150 kDa and theoretical pI 9.2. Traditionally Myeloperoxidase was considered as a main target of anti-neutrophil cytoplasm antibodies (ANCA), the serological markers for certain systemic vasculities e.g. periarteriitis nodosa, microscopic polyarteriitis and pulmonary eosinophilic granulomatosis (Churg-Strauss syndrome). Low to moderate anti-Myeloperoxidase autoantibody levels are also reported in rheumatoid arthritis. Recently it was shown that Myeloperoxidase participates in the initiation and progression of cardiovascular disease. It possesses potent proinflammatory properties and may contribute directly to tissue injury. Now Myeloperoxidase is under consideration as one of the most promising cardiac markers.